Department of Health Sciences, University "Magna Græcia" of Catanzaro, 88100 Catanzaro, Italy.
Department of Health Sciences, University "Magna Græcia" of Catanzaro, 88100 Catanzaro, Italy.
Curr Opin Pharmacol. 2021 Oct;60:1-10. doi: 10.1016/j.coph.2021.06.003. Epub 2021 Jul 14.
Maternal gestational diabetes mellitus (GDM) is one of the most common medical complications of pregnancy, which can adversely affect the short- and long-term health of mothers and newborns. In recent years, several studies have revealed the early impact of maternal hyperglycemia on fetal growth trajectory and birth weight abnormalities in GDM-exposed pregnancies. However, an intense debate continues regarding the mode and optimal timing of diagnosis and treatment of this condition. The purpose of this review is to provide a brief overview of the understanding of GDM and its implications for fetal growth, addressing the modulatory role of medical nutrition therapy and available pharmacological antidiabetic agents (i.e. insulin, metformin, and glyburide), and to identify gaps in current knowledge toward which future research should be directed.
母体妊娠期糖尿病(GDM)是妊娠期间最常见的医学并发症之一,可对母婴的短期和长期健康产生不利影响。近年来,多项研究揭示了母体高血糖对 GDM 暴露妊娠中胎儿生长轨迹和出生体重异常的早期影响。然而,对于这种情况的诊断和治疗方式及最佳时机,仍存在激烈的争论。本文旨在简要概述对 GDM 的认识及其对胎儿生长的影响,探讨医学营养疗法和现有降血糖药物(即胰岛素、二甲双胍和格列吡嗪)的调节作用,并确定当前知识中的空白领域,为未来研究指明方向。